News

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...
The new COVID-19 variant NB.1.8.1, known as Nimbus, is causing concern due to its subtle symptoms and high transmission rate.
GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...
Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...
A major new study examining the 2023-2024 COVID-19 vaccines shows moderate protection that works best in the first few months but weakens considerably over time. The research, published in JAMA ...
When Robert F Kennedy Jr announced that the US would stop recommending covid-19 vaccines for healthy children and pregnancies ...
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.